CureVac

CureVac, established in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mülbe, Günther Jung, and Hans-Georg Rammensee, is a global biotechnology company at the forefront of messenger RNA (mRNA) technology. The company's origins trace back to the discovery by its founders at the University of Tübingen that mRNA could be optimized and formulated for therapeutic use, a foundational insight for the subsequent development of mRNA-based medicines.

Operating from its headquarters in Tübingen, Germany, and additional sites across Europe and the U.S., CureVac has dedicated over two decades to refining its mRNA platform. The company's business model is centered on the research, development, and commercialization of a new class of therapies and vaccines. It operates in the global biotechnology market, with a focus on oncology, prophylactic vaccines, and molecular therapies. CureVac generates revenue through strategic partnerships with pharmaceutical companies and by advancing its proprietary product candidates through clinical development towards commercialization.

The company's product pipeline includes clinical and preclinical programs in several areas. In oncology, CureVac is developing off-the-shelf and personalized cancer vaccine candidates designed to elicit a specific anti-tumor response. Its work in prophylactic vaccines extends beyond its foundational contributions to COVID-19 vaccine technology to address other infectious diseases. Furthermore, CureVac is developing therapies that enable the body to produce its own therapeutic proteins, potentially treating a wide range of diseases.

Keywords: mRNA technology, biotechnology, cancer vaccines, prophylactic vaccines, oncology, therapeutic proteins, clinical development, biopharmaceutical, Tübingen, gene therapy